stockrow
Saturday 7 November 2026
Export DMRA’s income statement to Excel — free account
Galecto, Inc.
DMRA Healthcare Biotechnology
- EPS
- +78.1%
- Free cash flow
- −877.5%
Quarter to September 2026, against a year earlier
23.67
1.81
+8.28%
Follow DMRA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 11 | 11 | — | 0.0% | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (16) | (37) | (35) | (52) | (62) | (38) | (21) | (210) | (291) | +44.6% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (16) | (37) | (35) | (52) | (62) | (38) | (21) | (210) | (292) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (0.75) | (4,045.43) | (190.50) | (51.25) | (60.75) | (36.00) | (18.53) | (153.95) | 0.96 | +114.0% | ||||||
| Cash flow | — | — | (0.54) | (1,858.27) | (208.87) | (51.76) | (42.24) | (34.72) | (16.10) | (4.93) | (0.96) | +37.2% | ||||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | (0.22) | (0.19) | 0.08 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (0.54) | (1,858.27) | (208.87) | (51.99) | (42.43) | (34.65) | (16.10) | (4.93) | (0.96) | +37.2% | ||||||
| Book value | — | — | 1.21 | 4,660.67 | 904.81 | 116.00 | 60.76 | 30.41 | 13.68 | 176.36 | 8.02 | +103.9% | ||||||
| Shares, m | — | — | 25 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 40 | (34.2%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (14) | (19) | (38) | (52) | (43) | (37) | (19) | (7) | (59) | (9.7%) | |||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | — | — | 0 | n/m | ||||||
| Free cash flow | — | — | (14) | (19) | (38) | (53) | (43) | (37) | (19) | (7) | (59) | (9.7%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 31 | 48 | 164 | 106 | 53 | 31 | 16 | 240 | 495 | +34.3% | |||||
| Net debt | — | — | (31) | (11) | (164) | (100) | (60) | (33) | (14) | (258) | (528) | +35.3% | ||||||
| Shareholders’ equity | — | — | 31 | 48 | 165 | 117 | 62 | 32 | 16 | 240 | 496 | +34.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (108.28) | (91.74) | (30.53) | (35.23) | (63.07) | (68.84) | (77.45) | (3.90) | (27.08) | +104.4 pt | |||||
| ROIC | — | — | 0.00 | (65.52) | (1,102.42) | (191.65) | (2,501.92) | 0.00 | (840.13) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 36.21 | 80.14 | (73.85) | (36.61) | (68.86) | (81.52) | (91.62) | 6.72 | (39.51) | (29.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 20 | 28 | 40 | 45 | 13 | 5 | 7 | — | (16.1%) | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 6 Nov 2026
Galecto, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AAPG Ascentage Pharma Group International - Unsponsored ADR | $1.4B | — | — | — | — | +17.74% (above 0%: growing) | — | — | Compare |
| OCUL Ocular Therapeutix, Inc. | $1.4B | — (loss-making) | — (loss-making) | +0.12% (above 0%: growing) | n/m | −25.35% (below 0%: shrinking) | 85.08% | (609.34%) | Compare |
| KRSA Korsana Biosciences, Inc. | $1.4B | — (loss-making) | — (loss-making) | −43.24% (below 0%: shrinking) | n/m | −184.69% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ANAB AnaptysBio, Inc. | $1.4B | — (loss-making) | 220× | −7.98% (below 0%: shrinking) | n/m | −141.60% (below 0%: shrinking) | 100.00% | (135.53%) | Compare |
| GPCR Structure Therapeutics Inc. Sponsored ADR | $1.4B | — (loss-making) | — | — | n/m | −119.15% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DMRA Galecto, Inc. | $1.4B | 24.7× | — | — | n/m | −877.51% (below 0%: shrinking) | 0.00% | 0.00% | |
| MLYS Mineralys Therapeutics, Inc. | $1.4B | — (loss-making) | — | — | n/m | −7.91% (below 0%: shrinking) | — | 0.00% | Compare |
| TSHA Taysha Gene Therapies, Inc. | $1.3B | — (loss-making) | — (loss-making) | +206.77% (above 0%: growing) | n/m | −100.28% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KARD KARDIGAN INC | $1.3B | — (loss-making) | — | — | n/m | — | — | 0.00% | Compare |
| Median of peers | $1.4B | — | — | −3.93% | — | −100.28% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 29 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.30m | 2.13m | 127.83 |
| 2024 | 1.43m | 1.23m | 25.83 |
Ownership
Directors and executive officers, together
0.40%
Fairmount Funds Management LLC
19.99%
'Venrock Healthcare Capital Partners III, L.P.
5.98%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement